1. Market Research
  2. > Business Services
  3. > Research and Development Market Trends
  4. > X-BODY BioSciences, Inc. - Product Pipeline Review - 2014

X-BODY BioSciences, Inc. - Product Pipeline Review - 2014

  • December 2014
  • -
  • Global Markets Direct
  • -
  • 30 pages

X-BODY BioSciences, Inc. - Product Pipeline Review - 2014

Summary

Global Markets Direct’s, ‘X-BODY BioSciences, Inc. - Product Pipeline Review - 2014’, provides an overview of the X-BODY BioSciences, Inc.’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of X-BODY BioSciences, Inc.’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of X-BODY BioSciences, Inc. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of X-BODY BioSciences, Inc.’s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the X-BODY BioSciences, Inc.’s pipeline products

Reasons to buy

- Evaluate X-BODY BioSciences, Inc.’s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of X-BODY BioSciences, Inc. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the X-BODY BioSciences, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of X-BODY BioSciences, Inc. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of X-BODY BioSciences, Inc.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of X-BODY BioSciences, Inc. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

Table Of Contents

X-BODY BioSciences, Inc. - Product Pipeline Review - 2014
Table of Contents

X-BODY BioSciences, Inc. Snapshot 5
X-BODY BioSciences, Inc. Overview 5
Key Information 5
Key Facts 5
X-BODY BioSciences, Inc. - Research and Development Overview 6
Key Therapeutic Areas 6
X-BODY BioSciences, Inc. - Pipeline Review 9
Pipeline Products by Stage of Development 9
Pipeline Products - Monotherapy 10
X-BODY BioSciences, Inc. - Pipeline Products Glance 11
X-BODY BioSciences, Inc. - Early Stage Pipeline Products 11
Preclinical Products/Combination Treatment Modalities 11
Discovery Products/Combination Treatment Modalities 12
X-BODY BioSciences, Inc. - Drug Profiles 13
hMABs For Cancer 13
Product Description 13
Mechanism of Action 13
RandD Progress 13
XB-2202 14
Product Description 14
Mechanism of Action 14
RandD Progress 14
Monoclonal Antibodies to Target GCGR for Diabetes and Obesity 15
Product Description 15
Mechanism of Action 15
RandD Progress 15
Monoclonal Antibody for Autoimmune and Inflammation 16
Product Description 16
Mechanism of Action 16
RandD Progress 16
Monoclonal Antibody for Cancer 17
Product Description 17
Mechanism of Action 17
RandD Progress 17
Monoclonal Antibody to Activate Class B GPCR for Diabetes and Obesity 18
Product Description 18
Mechanism of Action 18
RandD Progress 18
Monoclonal Antibody to Antagonize CXCR4 for Cancer 19
Product Description 19
Mechanism of Action 19
RandD Progress 19
Monoclonal Antibody to Inhibit M3 for Irritable Bowel Syndrome 20
Product Description 20
Mechanism of Action 20
RandD Progress 20
Monoclonal Antibody to Inhibit NaV 1.7 for Pain 21
Product Description 21
Mechanism of Action 21
RandD Progress 21
Monoclonal Antibody to Inhibit TRPA1 for Pain 22
Product Description 22
Mechanism of Action 22
RandD Progress 22
X-BODY BioSciences, Inc. - Pipeline Analysis 23
X-BODY BioSciences, Inc. - Pipeline Products by Target 23
X-BODY BioSciences, Inc. - Pipeline Products by Molecule Type 24
X-BODY BioSciences, Inc. - Pipeline Products by Mechanism of Action 25
X-BODY BioSciences, Inc. - Recent Pipeline Updates 26
X-BODY BioSciences, Inc. - Dormant Projects 27
X-BODY BioSciences, Inc. - Locations And Subsidiaries 28
Head Office 28
Appendix 29
Methodology 29
Coverage 29
Secondary Research 29
Primary Research 29
Expert Panel Validation 29
Contact Us 30
Disclaimer 30

List of Tables

X-BODY BioSciences, Inc., Key Information 5
X-BODY BioSciences, Inc., Key Facts 5
X-BODY BioSciences, Inc. - Pipeline by Indication, 2014 8
X-BODY BioSciences, Inc. - Pipeline by Stage of Development, 2014 9
X-BODY BioSciences, Inc. - Monotherapy Products in Pipeline, 2014 10
X-BODY BioSciences, Inc. - Preclinical, 2014 11
X-BODY BioSciences, Inc. - Discovery, 2014 12
X-BODY BioSciences, Inc. - Pipeline by Target, 2014 23
X-BODY BioSciences, Inc. - Pipeline by Molecule Type, 2014 24
X-BODY BioSciences, Inc. - Pipeline Products by Mechanism of Action, 2014 25
X-BODY BioSciences, Inc. - Recent Pipeline Updates, 2014 26
X-BODY BioSciences, Inc. - Dormant Developmental Projects,2014 27

List of Figures

X-BODY BioSciences, Inc. - Pipeline by Top 10 Indication, 2014 7
X-BODY BioSciences, Inc. - Pipeline by Stage of Development, 2014 9
X-BODY BioSciences, Inc. - Monotherapy Products in Pipeline, 2014 10
X-BODY BioSciences, Inc. - Pipeline by Top 10 Target, 2014 23
X-BODY BioSciences, Inc. - Pipeline by Top 10 Molecule Type, 2014 24
X-BODY BioSciences, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2014 25

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Integrin Alpha 7 (ITGA7) - Pipeline Review, H2 2016

Integrin Alpha 7 (ITGA7) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Integrin Alpha 7 (ITGA7) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Integrin Alpha 7 (ITGA7) - Pipeline Review, H2 2016’, provides in depth analysis on Integrin Alpha 7 (ITGA7) ...

Pulmonary Fibrosis - Pipeline Review, H2 2016

Pulmonary Fibrosis - Pipeline Review, H2 2016

  • $ 2000
  • Company report
  • September 2016
  • by Global Markets Direct

Pulmonary Fibrosis - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Pulmonary Fibrosis - Pipeline Review, H2 2016’, provides an overview of the Pulmonary Fibrosis pipeline landscape. ...

Cognitive Impairment - Pipeline Review, H2 2016

Cognitive Impairment - Pipeline Review, H2 2016

  • $ 2000
  • Company report
  • September 2016
  • by Global Markets Direct

Cognitive Impairment - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Cognitive Impairment - Pipeline Review, H2 2016’, provides an overview of the Cognitive Impairment pipeline landscape. ...


ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.